July 21, 2024
You are here:  Home  >  Opinion  >  Editorials  >  Current Article

Our view: FTC’s overreach ends with Amgen ready to resume pushing innovation


In settling an antitrust lawsuit seeking to block the $28 billion merger of Amgen and Horizon Therapeutics, the Federal Trade Commission has stepped back from what looked like a classic case of overreach. The commission’s logic in trying to block the merger was that there was a hypothetical possibility that Amgen might try to bundle…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.